Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsFRA:BSFA -2.94%78 Gross Margin % is 60.59% as of Mar. 2026, which is 0% above its 10-year median of 60.32. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €83.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 942 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 70.06% on this metric.
ANI Pharmaceuticals (FRA:BSFA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ANI Pharmaceuticals had a gross margin of 60.59% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ANI Pharmaceuticals Gross Margin % Related Terms
ANI Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BSFA vs TRLV, AMLX, XERS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ANI Pharmaceuticals (FRA:BSFA) has a Gross Margin % of 60.59% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ANI Pharmaceuticals and its competitors. This is near median its historical median of 60.32. Over the past decade, ANI Pharmaceuticals' Gross Margin % has ranged from 53.45 to 69.42. According to the industry distribution chart, ANI Pharmaceuticals ranks #282 out of 942 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is ANI Pharmaceuticals' Gross Margin % too high?
ANI Pharmaceuticals' current Gross Margin % of 60.59% is near median its 10-year median of 60.32. Over the past 10 years, this metric has ranged from a low of 53.45 to a high of 69.42. The Drug Manufacturers industry median Gross Margin % is 48.50. ANI Pharmaceuticals' value of 60.59% is 24.9% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #282 out of 942 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Gross Margin % compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #282 out of 942 companies for Gross Margin %. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 48.50. ANI Pharmaceuticals' value of 60.59% is 24.9% above this benchmark. Historically, ANI Pharmaceuticals' own Gross Margin % has ranged from 53.45 to 69.42 over the past decade. While the company's 10-year median is 60.32 vs. the industry median of 48.50, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current Gross Margin % of 60.59% is 24.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current Gross Margin % is 60.59%, which is near median its own 10-year median of 60.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.99, compared to a current price of €66.00 — trading 21.4% below its estimated fair value. The current Gross Margin % is 60.59%, which is near median its 10-year median of 60.32 and 24.9% above the Drug Manufacturers industry median of 48.50. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Gross Margin % is 60.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of €66.00 is trading 21.4% below its estimated GF Value™ of €83.99.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for FRA:BSFA:
Gross Margin %: 60.59% (near median its 10-year median of 60.32)
GF Value™: €83.99 vs. price of €66.00 (21.4% below fair value)
Industry Position: 24.9% above the Drug Manufacturers median (#282 of 942)
No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score
Get the complete analysis for FRA:BSFA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BSFA has been successfully added to your 
